Profile data is unavailable for this security.
About the company
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. It is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. It has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. It is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.
- Revenue in AUD (TTM)35.26k
- Net income in AUD-229.57m
- Incorporated1984
- Employees5.00
- LocationOpthea LtdSuite 0403Level 4, 650 Chapel Street, South YarraMELBOURNE 3141AustraliaAUS
- Phone+61 39826-0399
- Fax+61 39824-0083
- Websitehttps://opthea.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nyrada Inc | 2.56m | -4.85m | 198.41m | -- | -- | 47.76 | -- | 77.54 | -0.0243 | -0.0243 | 0.0128 | 0.017 | 0.4566 | -- | -- | -- | -86.47 | -48.87 | -112.02 | -53.88 | -- | -- | -189.37 | -195.83 | -- | -- | 0.00 | -- | -24.81 | 18.93 | -248.28 | -- | -- | -- |
| Dimerix Ltd | 5.91m | -13.25m | 318.21m | 0.00 | -- | 23.71 | -- | 53.81 | -0.0239 | -0.0239 | 0.0106 | 0.0224 | 0.096 | -- | 22.53 | -- | -21.50 | -48.20 | -27.12 | -68.49 | -- | -- | -224.08 | -932.89 | -- | -- | 0.0072 | -- | 913.54 | 365.69 | 22.39 | -- | -- | -- |
| Cogstate Ltd | 74.87m | 14.31m | 370.56m | 61.00 | 26.26 | 5.40 | 20.07 | 4.95 | 0.0823 | 0.0823 | 0.4303 | 0.3999 | 0.866 | -- | 4.69 | -- | 16.55 | 11.82 | 20.98 | 16.38 | 60.53 | 56.32 | 19.11 | 14.87 | -- | -- | 0.0097 | -- | 22.25 | 18.44 | 86.15 | -- | -0.4007 | -- |
| Racura Oncology Ltd | 788.42k | -4.79m | 444.72m | -- | -- | 26.59 | -- | 564.06 | -0.0282 | -0.0282 | 0.0043 | 0.0922 | 0.0418 | -- | 11.64 | -- | -25.38 | -41.75 | -27.84 | -44.07 | -- | -- | -607.20 | -2,015.76 | -- | -- | 0.00 | -- | -5.30 | 142.92 | 65.36 | -- | -- | -- |
| Immutep Ltd | 60.10k | -61.43m | 552.65m | 19.00 | -- | 3.81 | -- | 9,195.43 | -0.0422 | -0.0422 | 0.00004 | 0.0984 | 0.0003 | -- | 0.0991 | -- | -34.27 | -32.47 | -36.64 | -34.65 | -- | -- | -102,219.90 | -21,963.05 | -- | -- | 0.0112 | -- | -49.76 | -62.18 | -43.82 | -- | 69.56 | -- |
| Opthea Ltd | 35.26k | -229.57m | 820.79m | 5.00 | -- | -- | -- | 23,280.77 | -0.188 | -0.188 | 0.00003 | -0.2303 | 0.0002 | -- | 0.1324 | -- | -132.57 | -123.14 | -- | -214.28 | -- | -- | -651,164.00 | -159,023.40 | -- | -11.15 | -- | -- | -79.95 | -15.80 | 26.09 | -- | 38.73 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -64.30m | 1.22bn | -- | -- | 11.65 | -- | -- | -0.2011 | -0.2011 | 0.00 | 0.2807 | 0.00 | -- | -- | -- | -50.27 | -40.38 | -54.18 | -43.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.91 | -- | 65.99 | -- |
| PYC Therapeutics Ltd | 26.17m | -50.30m | 1.38bn | 23.00 | -- | 5.24 | -- | 52.77 | -0.0987 | -0.0987 | 0.0511 | 0.2824 | 0.1907 | -- | 66.76 | -- | -37.17 | -42.88 | -40.47 | -47.98 | -- | -- | -194.92 | -172.76 | -- | -39.28 | 0.006 | -- | 14.51 | 58.66 | -33.34 | -- | 55.85 | -- |
| Mesoblast Ltd | 24.25m | -144.04m | 3.23bn | 81.00 | -- | 3.80 | -- | 133.00 | -0.1192 | -0.1192 | 0.0201 | 0.6583 | 0.0237 | -- | 2.25 | 299,423.60 | -14.05 | -13.19 | -15.99 | -14.68 | 70.17 | -132.14 | -593.92 | -957.40 | 1.77 | -4.50 | 0.1766 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Telix Pharmaceuticals Ltd | 940.97m | 15.64m | 3.41bn | 234.00 | 236.96 | 5.72 | 102.71 | 3.62 | 0.0425 | 0.0425 | 2.69 | 1.76 | 0.7909 | 11.01 | 7.28 | -- | 1.31 | -10.99 | 1.82 | -15.18 | 54.00 | 61.79 | 1.66 | -13.10 | 1.22 | -- | 0.4978 | -- | 54.81 | 192.25 | 851.60 | -- | 150.32 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Regal Funds Management Pty Ltd.as of 05 Sep 2025 | 321.14m | 0.00% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 43.24m | 0.00% |
| BlackRock Asset Management North Asia Ltd.as of 31 Oct 2025 | 3.78m | 0.00% |
| Pictet Asset Management SAas of 30 Jun 2025 | 2.59m | 0.00% |
| Charles Schwab Investment Management, Inc.as of 08 Jan 2026 | 2.28m | 0.00% |
| Vanguard Fiduciary Trust Co.as of 30 Nov 2025 | 1.33m | 0.00% |
| Pictet Asset Management (Singapore) Pte Ltd.as of 30 Jun 2025 | 1.05m | 0.00% |
| Russell Investment Management Ltd.as of 30 Sep 2025 | 813.55k | 0.00% |
| Vanguard Asset Management Ltd.as of 31 Dec 2025 | 291.32k | 0.00% |
| Vanguard Global Advisers LLCas of 31 Dec 2025 | 232.40k | 0.00% |
